Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Te‐Chun Hsia

ResearcherPublications, citations & collaboration network

Te‐Chun Hsia is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 294 works, 7,498 citations, an h-index of 29 and an i10-index of 85.

294
Works
7,498
Citations
29
h-index
85
i10-index

How has Te‐Chun Hsia's publication output changed over time?

ScholarIQpublication output · 1996–2024

Output grew0% over the shown period — from 1 works in 1996 to 1 in 2024.

1
1
1
2
1
2
1
1
1
199620092018201920202021202220232024

What are the most-cited papers on Te‐Chun Hsia?

ScholarIQmost cited works
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz
The Lancet. 20192,246 Citations
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz‐Ares, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Nataliia Voitko, Artem Poltoratskiy, Igor Bondarenko, Yuanbin Chen, Andrzej Każarnowicz, Luis Paz‐Ares, Mustafa Özgüroğlu, Nikolay Conev, Maximilian J. Hochmair, Otto C. Burghuber, Libor Havel, İrfan Çiçin, György Losonczy, В. Моисеенко, Mustafa Erman, Dariusz M. Kowalski, Marek Z. Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Niels Reinmuth, Jun Ho Ji, Maria Amelia Insa Molla, Grygorii Ursol, Anne C. Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Francesco Verderame, Katsuyuki Hotta, Sang‐We Kim, Alexey Smolin, Tuncay Göksel, Shaker R. Dakhil, Jaromı́r Roubec, Krisztina Bogos, Marina Chiara Garassino, Robin Cornelissen, Jong-Seok Lee, M.R. García Campelo, Marta López Brea, Ahmet Alacacıoğlu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, A Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong‐Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, M. Majem Tarruella, David R. Spigel, Krassimir Koynov, Milada Zemanová, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Sławomir Mańdziuk
The Lancet Oncology. 2020700 CitationsOPEN ACCESS
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz‐Ares, Chao‐Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin‐Yuan Shih, Kwok Hung Au, Denis Moro‐Sibilot, Sotaro Enatsu, Annamaria H. Zimmermann, Bente Frimodt‐Moller, Carla Visseren‐Grul, Martin Reck, Quincy S. Chu, Alexis B. Cortot, Jean-Louis Pujol, Denis Moro‐Sibilot, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Reck, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, Jcm Ho, Kwok‐Hung Au, Silvia Novello, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Kazuhiko Nakagawa, Makoto Nishio, Kiyotaka Yoh, Takashi Seto, Fumio Imamura, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Toru Kumagai, Keisuke Aoe, Toru Kumagai, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Keunchil Park, Sang‐We Kim, Young Joo Min, Hyun Woo Lee, Jin‐Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong‐Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan
The Lancet Oncology. 2019616 CitationsOPEN ACCESS
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark
The Lancet Oncology. 2018578 CitationsOPEN ACCESS
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te‐Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, for the KEYNOTE-598 Investigators
Journal of Clinical Oncology. 2021256 CitationsOPEN ACCESS

Related on ScholarIQ

China Medical University
Institution
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paper
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Paper
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Paper
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Paper
470M+ articles · free account